Our treatment, called STA363, addresses instability and leakage of pain-producing molecules in degenerating disks, the core causes of chronic low back pain (cLBP), by injecting a therapeutic agent into the disc. The substance is well documented and has been used for decades in humans allowing a relatively fast, inexpensive and low-risk route to market.
The treatment in short
The STA363 treatment is a world unique, patent pending innovation to stabilise degenerated discs. Discogenic cLBP often resolves spontaneously over time as the disc becomes sclerotic and stiff, and STA363 shortens this process from decades to a few months. Instead of costly and time-consuming procedures, such as spinal fusions or long-term physiotherapy, STA363 is administered as a one-time injection. STA363 was invented by Professor Kjell Olmarker at the Institute of Biomedicine, Sahlgrenska Academy, Sweden and a phase 1b clinical trial has been successfully completed.